Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css–MRTpo method and chimeric mice with humanised livers

References

• Anderson S, Luffer-Atlas D, Knadler MP. 2009. Predicting circulating human metabolites: how good are we? Chem Res Toxicol. 22(2):243–256. doi: 10.1021/tx8004086.
   PubMed Web of Science ®Google Scholar
• Asano D, Hamaue S, Zahir H, Shiozawa H, Nishiya Y, Kimura T, Kazui M, Yamamura N, Ikeguchi M, Shibayama T, et al. 2022. CYP2C8-Mediated formation of a human disproportionate metabolite of the selective NaV1.7 inhibitor DS-1971a, a mixed cytochrome P450 and aldehyde oxidase substrate. Drug Metab Dispos. 50(3):235–242. doi: 10.1124/dmd.121.000665.
   PubMed Web of Science ®Google Scholar
• Asano D, Nakamura K, Nishiya Y, Shiozawa H, Takakusa H, Shibayama T, Inoue S, Shinozuka T, Hamada T, Yahara C, et al. 2023. Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Nav1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver. Drug Metab Dispos. 51(1):67–80. doi: 10.1124/dmd.122.001000.
   PubMed Web of Science ®Google Scholar
• Asano D, Shibayama T, Shiozawa H, Inoue SI, Shinozuka T, Murata S, Watanabe N, Yoshinari K. 2021. Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase. Xenobiotica. 51(9):1060–1070. doi: 10.1080/00498254.2021.1963009.
   PubMed Web of Science ®Google Scholar
• Bai A, Shanmugasundaram V, Selkirk JV, Surapaneni S, Dalvie D. 2021. Investigation into MAO B-mediated formation of CC112273, a major circulating metabolite of ozanimod, in humans and preclinical species: stereospecific oxidative deamination of (S)-enantiomer of indaneamine (RP101075) by MAO B. Drug Metab Dispos. 49(8):601–609. doi: 10.1124/dmd.121.000447.
   PubMed Web of Science ®Google Scholar
• Barzi M, Pankowicz FP, Zorman B, Liu X, Legras X, Yang D, Borowiak M, Bissig-Choisat B, Sumazin P, Li F, et al. 2017. Erratum: a novel humanized mouse lacking murine p450 oxidoreductase for studying human drug metabolism. Nat Commun. 8(1):984. doi: 10.1038/s41467-017-01314-9.
   PubMedGoogle Scholar
• Benet LZ, Sodhi JK. 2022. Can in vitro-in vivo extrapolation be successful? Recognizing the incorrect clearance assumptions. Clin Pharmacol Ther. 111(5):1022–1035. doi: 10.1002/cpt.2482.
   PubMed Web of Science ®Google Scholar
• Bissig KD, Han W, Barzi M, Kovalchuk N, Ding L, Fan X, Pankowicz FP, Zhang Q-Y, Ding X. 2018. P450-humanized and human liver chimeric mouse models for studying xenobiotic metabolism and toxicity. Drug Metab Dispos. 46(11):1734–1744. doi: 10.1124/dmd.118.083303.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, et al. 2009. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol. 22(2):357–368. doi: 10.1021/tx8004357.
   PubMed Web of Science ®Google Scholar
• Darwish M, Martin PT, Cevallos WH, Tse S, Wheeler S, Troy SM. 1999. Rapid disappearance of zaleplon from breast milk after oral administration to lactating women. J Clin Pharmacol. 39(7):670–674. doi: 10.1177/00912709922008308.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095. doi: 10.1023/a:1018943613122.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency 2009. ICH topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. London, UK: european Medicines Agency.
   Google Scholar
• Food and Drug Administration 2008. Guidance for Industry: safety testing of drug metabolites. Rockville (MD): FDA.
   Google Scholar
• Fura A, Vyas V, Humphreys W, Chimalokonda A, Rodrigues D. 2008. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds. Biopharm Drug Dispos. 29(8):455–468. doi: 10.1002/bdd.632.
   PubMed Web of Science ®Google Scholar
• Hjermitslev M, Grimm DG, Wehland M, Simonsen U, Krüger M. 2017. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension. Basic Clin Pharmacol Toxicol. 121(4):225–233. doi: 10.1111/bcpt.12800.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 49(5):513–533. doi: 10.1177/0091270009333209.
   PubMed Web of Science ®Google Scholar
• Ito S, Kamimura H, Yamamoto Y, Chijiwa H, Okuzono T, Suemizu H, Yamazaki H. 2020. Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. Drug Metab Pharmacokinet. 35(6):505–514. doi: 10.1016/j.dmpk.2020.07.004.
   PubMed Web of Science ®Google Scholar
• Kambayashi A, Shirasaka Y. 2023. Food effects on gastrointestinal physiology and drug absorption. Drug Metab Pharmacokinet. 48:100488. doi: 10.1016/j.dmpk.2022.100488.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S. 2016. Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica. 46(6):557–569. doi: 10.3109/00498254.2015.1091113.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, Okuzono T, Ishiguro T, Yamamoto Y, Nishinoaki S, Ninomiya S, Mitsui M, Kalgutkar AS, et al. 2017. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica. 47(5):382–393. doi: 10.1080/00498254.2016.1199063.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Nozawa K, Nakamura S, Chijiwa H, Nagatsuka S, Kuronuma M, Ohnishi Y, Suemizu H, Ninomiya S. 2015. Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos. 43(3):309–316. doi: 10.1124/dmd.114.061689.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, Murakami Y, Tanaka K, Iwatsubo T, Kawamura A, Usui T. 2010. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet. 25(3):223–235. doi: 10.2133/dmpk.25.223.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Uehara S, Suemizu H. 2020. A novel Css-MRTpo approach to simulate oral plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using chimeric mice with humanized livers. Xenobiotica. 50(7):761–768. doi: 10.1080/00498254.2019.1693082.
   PubMed Web of Science ®Google Scholar
• Kato K, Ohbuchi M, Hamamura S, Ohshita H, Kazuki Y, Oshimura M, Sato K, Nakada N, Kawamura A, Usui T, et al. 2015. Development of murine Cyp3a knockout chimeric mice with humanized liver. Drug Metab Dispos. 43(8):1208–1217. doi: 10.1124/dmd.115.063479.
   PubMed Web of Science ®Google Scholar
• Kato S, Shah A, Plesescu M, Miyata Y, Bolleddula J, Chowdhury S, Zhu X. 2020. Prediction of human disproportionate and biliary excreted metabolites using chimeric mice with humanized liver. Drug Metab Dispos. 48(10):934–943. doi: 10.1124/dmd.120.000128.
   PubMed Web of Science ®Google Scholar
• Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, Yokoi T. 2007. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci. 96(2):428–437. doi: 10.1002/jps.20783.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Ebihara T, Takeuchi T, Morohashi A, Yamasaki H, Tagawa Y, Takahashi J, Kondo T, Asahi S. 2013. Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals. Xenobiotica. 43(2):182–192. doi: 10.3109/00498254.2012.708797.
   PubMed Web of Science ®Google Scholar
• Kenyon CJ, Hooper G, Tierney D, Butler J, Devane J, Wilding IR. 1995. The effect of food on the gastrointestinal transit and systemic absorption of naproxen from a novel sustained release formulation. J Control Release. 34(1):31–36. doi: 10.1016/0168-3659(94)00118-E.
   Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmöller J. 2003. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol. 55(1):51–61. doi: 10.1046/j.1365-2125.2003.01712.x.
   PubMed Web of Science ®Google Scholar
• Kuze Y, Kogame A, Jinno F, Kondo T, Asahi S. 2015. Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 1001:174–181. doi: 10.1016/j.jchromb.2015.07.047.
   PubMed Web of Science ®Google Scholar
• Langguth P, Marroum P. 2012. Relationships between in vitro drug dissolution and in vivo response. Biopharm Drug Dispos. 33(7):347–348. doi: 10.1002/bdd.1808.
   PubMed Web of Science ®Google Scholar
• Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, et al. 2011. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor. Drug Metab Dispos. 39(10):1840–1849. doi: 10.1124/dmd.111.040840.
   PubMed Web of Science ®Google Scholar
• Lutz JD, Fujioka Y, Isoherranen N. 2010. Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opin Drug Metab Toxicol. 6(9):1095–1109. doi: 10.1517/17425255.2010.497487.
   PubMed Web of Science ®Google Scholar
• Lutz JD, Isoherranen N. 2012. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos. 40(1):159–168. doi: 10.1124/dmd.111.042200.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Kamimura H, Nishiwaki M, Cho N, Kato K, Yamamoto T. 2021. Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism. Xenobiotica. 51(9):983–994. doi: 10.1080/00498254.2021.1950865.
   PubMed Web of Science ®Google Scholar
• Miura T, Uehara S, Shimizu M, Suemizu H, Yamazaki H. 2021. Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes. J Toxicol Sci. 46(7):311–317. doi: 10.2131/jts.46.311.
   PubMed Web of Science ®Google Scholar
• Miyake T, Tsutsui H, Hirabayashi M, Tachibana T. 2023. Quantitative prediction of OATP-mediated disposition and biliary clearance using human liver chimeric mice. J Pharmacol Exp Ther. 387(2):135–149. doi: 10.1124/jpet.123.001595.
   PubMedGoogle Scholar
• Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Hirabayashi H. 2017. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica. 47(12):1052–1063. doi: 10.1080/00498254.2016.1265160.
   PubMed Web of Science ®Google Scholar
• Obach RS, Lin J, Kimoto E, Duvvuri S, Nicholas T, Kadar EP, Tremaine LM, Sawant-Basak A. 2018. Estimation of circulating drug metabolite exposure in human using in vitro data and physiologically based pharmacokinetic modeling: example of a high metabolite/parent drug ratio. Drug Metab Dispos. 46(2):89–99. doi: 10.1124/dmd.117.078279.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M. 2007. In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica. 37(10-11):1066–1089. doi: 10.1080/00498250701620726.
   PubMed Web of Science ®Google Scholar
• PMDA (Pharmaceuticals and Medical Devices Agency). [date unknown]. Approval document for azilsartan; available from: http://www.pmda.go.jp; 400256000_22400AMX00038_I100_2.pdf (Japanese).
   Google Scholar
• Sanoh S, Naritomi Y, Fujimoto M, Sato K, Kawamura A, Horiguchi A, Sugihara K, Kotake Y, Ohshita H, Tateno C, et al. 2015. Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica. 45(7):605–614. doi: 10.3109/00498254.2015.1007112.
   PubMed Web of Science ®Google Scholar
• Sawada T, Yamaura Y, Higuchi S, Imawaka H, Yamazaki H. 2020. Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver. Xenobiotica. 50(5):526–535. doi: 10.1080/00498254.2019.1664791.
   PubMed Web of Science ®Google Scholar
• Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, et al. 2018. A decade in the MIST: learnings from Investigations of drug metabolites in drug development under the "Metabolites in Safety Testing" regulatory guidance. Drug Metab Dispos. 46(6):865–878. doi: 10.1124/dmd.117.079848.
   PubMed Web of Science ®Google Scholar
• Schulz-Utermoehl T, Sarda S, Foster JR, Jacobsen M, Kenna JG, Morikawa Y, Salmu J, Gross G, Wilson ID. 2012. Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Xenobiotica. 42(6):503–517. doi: 10.3109/00498254.2011.640716.
   PubMed Web of Science ®Google Scholar
• Sharma R, Bergman A, Litchfield J, Atkinson K, Kazierad DJ, Kalgutkar AS. 2019. Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies. Xenobiotica. 49(12):1447–1457. doi: 10.1080/00498254.2019.1581960.
   PubMed Web of Science ®Google Scholar
• Sharma R, Litchfield J, Atkinson K, Eng H, Amin NB, Denney WS, Pettersen JC, Goosen TC, Di L, Lee E, et al. 2014. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos. 42(11):1926–1939. doi: 10.1124/dmd.114.060087.
   PubMedGoogle Scholar
• Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR. 1978. The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol. 5(1):27–34. doi: 10.1111/j.1365-2125.1978.tb01594.x.
   PubMed Web of Science ®Google Scholar
• Tanoue C, Sugihara K, Uramaru N, Tayama Y, Watanabe Y, Horie T, Ohta S, Kitamura S. 2013. Prediction of human metabolism of the sedative-hypnotic zaleplon using chimeric mice transplanted with human hepatocytes. Xenobiotica. 43(11):956–962. doi: 10.3109/00498254.2013.788232.
   PubMed Web of Science ®Google Scholar
• Uehara S, Higuchi Y, Yoneda N, Kawai K, Yamamoto M, Kamimura H, Iida Y, Oshimura M, Kazuki Y, Yamazaki H, et al. 2022a. An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals. Drug Metab Pharmacokinet. 42:100410. doi: 10.1016/j.dmpk.2021.100410.
   PubMed Web of Science ®Google Scholar
• Uehara S, Iida Y, Ida-Tanaka M, Goto M, Kawai K, Yamamoto M, Higuchi Y, Ito S, Takahashi R, Kamimura H, et al. 2022b. Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism. Sci Rep. 12(1):14907. doi: 10.1038/s41598-022-19242-0.
   PubMed Web of Science ®Google Scholar
• Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. 2021. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug Metab Pharmacokinet. 41:100419. doi: 10.1016/j.dmpk.2021.100419.
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci. 100(10):4111–4126. doi: 10.1002/jps.22551.
   PubMed Web of Science ®Google Scholar
• Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci. 93(7):1890–1900. doi: 10.1002/jps.20099.
   PubMed Web of Science ®Google Scholar
• Wiśniowska B, Giebułtowicz J, Piotrowski R, Kułakowski P, Polak S. 2022. Development and performance verification of the PBPK model for antazoline and its metabolite and its utilization for pharmacological hypotheses formulating. Pharmaceuticals (Basel). 15(3):379. doi: 10.3390/ph15030379.
   PubMedGoogle Scholar
• Wu X, Meng J, Yuan H, Zhong D, Yu J, Cao G, Liu X, Guo B, Chen Y, Li Y, et al. 2021. Pharmacokinetics and disposition of contezolid in humans: resolution of a disproportionate human metabolite for clinical development. Antimicrob Agents Chemother. 65(11):e0040921. doi: 10.1128/AAC.00409-21.
   PubMed Web of Science ®Google Scholar
• Young MA, Lettis S, Eastmond R. 1998. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br J Clin Pharmacol. 45(1):31–35. doi: 10.1046/j.1365-2125.1998.00653.x.
   PubMed Web of Science ®Google Scholar
• Zhang T, Heimbach T, Lin W, Zhang J, He H. 2015. Prospective predictions of human pharmacokinetics for eighteen compounds. J Pharm Sci. 104(9):2795–2806. doi: 10.1002/jps.24373.
   PubMed Web of Science ®Google Scholar
• Zheng J, Xin Y, Zhang J, Subramanian R, Murray BP, Whitney JA, Warr MR, Ling J, Moorehead L, Kwan E, et al. 2018. Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 46(3):237–247. doi: 10.1124/dmd.117.078899.
   PubMed Web of Science ®Google Scholar